Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Martha Q Lacy,Morie A Gertz,Amylou C Dueck,Francis K Buadi,John A Lust,Eli Muchtar,Mark R Litzow,Shruthi Naik,Stephen J Russell,David Dingli,Taxiarchis Kourelis,Mrinal M Patnaik,Robert A Kyle,S Vincent Rajkumar,Rahma Warsame,Thomas E Witzig,Nelson Leung,Angela Dispenzieri,Ronald S Go,Suzanne R Hayman,Prashant Kapoor,Robert C Murphy ,Kah-Whye Peng ,Stephen M Broski ,Mark J Federspiel ,Steven R Zeldenrust ,Brenda Ginos ,Wilson I Gonsalves ,Aref Al‐Kali ,Shaji Kumar

doi:10.1182/blood-2018-99-119444

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Martha Q Lacy, Morie A Gertz + Show 28 more

Open Access

https://doi.org/10.1182/blood-2018-99-119444

Copy DOI

Journal: Blood

Publication Date: Nov 29, 2018

Affiliation: Mayo Clinic

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Full Text